Guardant Health Amends Executive Compensation Arrangements

TL;DR

**Guardant Health just tweaked executive pay, watch for impact on leadership and costs.**

AI Summary

Guardant Health, Inc. filed an 8-K on February 1, 2024, reporting an event on January 26, 2024, related to changes in its executive compensation arrangements. This filing indicates that the company is making adjustments to how it compensates its key officers, which could impact future financial performance and executive retention. For investors, understanding these changes is crucial as executive compensation can influence management's incentives and the company's overall cost structure, potentially affecting stock valuation.

Why It Matters

Changes in executive compensation can signal shifts in company strategy or financial health, directly impacting investor confidence and the company's ability to attract and retain top talent.

Risk Assessment

Risk Level: medium — While not inherently negative, changes in executive compensation can introduce uncertainty regarding leadership stability and future financial commitments, warranting investor attention.

Analyst Insight

A smart investor would monitor Guardant Health's upcoming filings for specific details on the executive compensation changes to assess their potential impact on the company's financial health and executive incentives.

Key Players & Entities

• Guardant Health, Inc. (company) — the registrant filing the 8-K
• January 26, 2024 (date) — date of the earliest event reported
• February 1, 2024 (date) — date the 8-K was filed
• Delaware (company) — state of incorporation for Guardant Health, Inc.
• 001-38683 (dollar_amount) — Commission File Number

Forward-Looking Statements

• Guardant Health will provide more specific details on the executive compensation changes in its next quarterly or annual report. (Guardant Health, Inc.) — high confidence, target: Q1 2024 Earnings Report

FAQ

From the Filing

0001193125-24-021871.txt : 20240201 0001193125-24-021871.hdr.sgml : 20240201 20240201162032 ACCESSION NUMBER: 0001193125-24-021871 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240126 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240201 DATE AS OF CHANGE: 20240201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 24587221 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 d745810d8k.htm 8-K 8-K false 0001576280 0001576280 2024-01-26 2024-01-26     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2024     GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38683   45-4139254 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.) 3100 Hanover Street Palo Alto , California 94304 (Address of principal executive offices) (Zip Code) 855 - 698-8887 (Registrant’s telephone number, include area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 26, 2024, Mr. Samir Kaul notified the board of directors (the “Board”) of Guardant Health, Inc. (the “Company”) that he intends to resign as member of the Board and as a member of the compensation committee of the Board effective February 1, 2024. Mr. Kaul’s resignation is not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company. Effective upon Mr. Kaul’s r